CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Faculdade de Medicina de Ribeirão Preto (FMRP) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Fabiola Traina graduated in Medicine at UNICAMP (1997) where she also completed a medical residency in Hematology and Hemotherapy (1998-2000) and Bone Marrow Transplantation (2001), with complementary training in Bone Marrow Transplantation at the Seattle Cancer Cell Alliance (Seattle, USA) (2003). She obtained her doctorate in Medical Physiopathology at the State University of Campinas (2007) and postdoctorate at the Cleveland Clinic (Ohio, USA) (2011). She worked as a hematologist and collaborating researcher at UNICAMP between 2004 and 2013. In 2013, she assumed the position of Professor at the Department of Internal Medicine at FMRP USP. Currently, she is Full Professor (MS-5) at the Department of Medical Imaging, Hematology and Oncology at FMRP USP, Vice-Coordinator of the Department, Coordinator and Supervisor of the Bone Marrow Transplant Center at HC FMRP USP and Scientific Technical Director at Hemocentro from Ribeirão Preto. In addition to dedicating herself to the teaching of graduation, post-graduation and extension activities, she is engaged in translational research with interest in the study of cytogenetic/molecular alterations and new therapeutic strategies in myeloid neoplasias. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Myelodysplastic syndrome (MDS) is a heterogeneous group of hematological neoplasms characterized by ineffective hematopoiesis, cytopenias and risk of progression to acute myeloid leukemia and which mainly affects the elderly population. Mitochondrial dysfunction and stem cell exhaustion are two hallmarks of aging commonly found in MDS. Clonal hematopoiesis is perpetuated by inflammation a…
We propose a program of basic and clinical research to isolate, culture, and characterize embryonic ,somatic, and neoplastic stem cells in order to understand their biology and apply this knowledge to therapy, comprising four research lines: (1) pluripotent stem cells (SC) (embryonic SC and induced pluripotent SC); (2) somatic SC (hematopoietic SC, mesenchymal SC, endothelial SC, and canc…
Myeloproliferative neoplasia originates from the hematopoietic stem cell, are characterized by JAK/STAT signaling activation, and decontrolled proliferation of one or more cells of the myeloid lineage. Patients may present changes in hematimetric counts, splenomegaly, and thromboembolic events, and evolve with increased fibrosis in the bone marrow and acute myeloid leukemia. The only pote…
Hematopoiesis is a process finely regulated by cytokines and growth factors. The regulation of these molecules depends, among other factors, on the action of cytoplasmic adapter proteins, such as insulin receptor substrates (IRS). IRS activation promotes the recruitment of effector proteins involved in the regulation of JAK/STAT, PI3K/AKT/mTOR and MAPK signaling. These signaling pathways …
The BCR-ABL1 negative chronic myeloproliferative neoplasms (MPN) are characterized by increased cellular proliferation with preserved terminal myeloid differentiation. In most cases, the activation of cell proliferation is caused by an increased tyrosine kinase activity of specific proteins. However, patients' molecular heterogeneity and the incomplete clinical responses observed in part …
(Only some records are available in English at this moment)
Myelodysplastic syndrome (MDS) is a heterogeneous group of hematological malignancies characterized by ineffective hematopoiesis, cytopenias and risk of progression to acute myeloid leukemia, which mainly affects the elderly population. Mitochondrial dysfunction and stem cell exhaustion are two features of aging commonly found in MDS. Clonal hematopoiesis is perpetuated by inflammation an…
Acute Myeloid Leukemia (AML) is an aggressive malignant neoplasm that leads to bone marrow failure and has a high potential for infiltration into other organs, often proving fatal if left untreated. AML accounts for approximately 1.9% of cancer-related deaths. Furthermore, data from the same institute indicate that this tumor predominantly affects middle-aged adults, with over 2/3 of case…
Acute myeloid leukemia (AML) comprehends a heterogeneous and complex group of hematological neoplasms characterized by the affection of hematopoietic stem and progenitor cells by (epi)genetic insults that trigger these cells clonal expansion, hypofunctional cells accumulation and bone marrow remodeling that leads to impairment of normal hematopoiesis.AML's biology has been extensively stu…
FLT3 gene mutations are present on near 30% of the acute myeloid leukemia (AML) patients with FLT3-ITD being the most frequent among other FLT3 mutations and related to a poor prognosis. The development of FLT3 inhibitors stated an improvement on AML treatment since they are able to reduce cell proliferation and ameliorate patients' survival. However, clinical limitations on using these d…
(Only some records are available in English at this moment)
Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm (MPN). The overlapping features of CNL with others rare myeloid malignancies, have been challenging the differential diagnosis and the development of therapies. Mutations in the CSF3R gene, which encodes the granulocyte colony stimulating factor receptor (G-CSFR), occur in CNL and result in the activation of JAK/STA…
Chronic myeloid leukemia (CML) is a hematological malignancy associated with the BCR-ABL1 fusion gene, which drives the proliferative disease phenotype by activating multiple signaling pathways. Most CML patients are successfully treated with tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1. However, acquired drug resistance limits TKI efficacy in a significant subset of patients, war…
| 2 / 2 | Ongoing grants |
| 9 / 8 | Completed research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 18 / 17 | Completed scholarships in Brazil |
| 2 / 2 | Completed scholarships abroad |
| 32 / 30 | All research grants and scholarships |
| Associated processes | |